The effect of a novel 5HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease

A. Rydzewski, T. Hachiya, T. Urano

Research output: Contribution to journalArticle

Abstract

The effect of a new, specific 5-HT2 receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease, was assessed in a pilot study. We investigated 10 patients suffering from Buerger's disease. Sarpogrelate in a dose of 3 × 100mg a day was given p.o. for a period of 8 weeks. It was well tolerated and no major side effects were noted. Sarpogrelate induced significant decrease in plasma serotonin concentration starting after 4th week which lasted through 8 weeks of the study, whereas plasma tryptophan concentration increased significantly after 2 and 4 weeks. There were no changes in plasma 5-HIAA concentration. On the other hand whole blood 5-HT concentration increased significantly alter 2 weeks, and there was also nearly significant increase in whole blood tryptophan concentration (p =0.052). Platelet aggregation induced by ADP and collagen did not show any statistically significant changes. Surprisingly, platelet aggregation induced by serotonin increased significantly after 2 weeks and even more so after 4 weeks of treatment and returned to baseline values after 8 weeks. Concentrations of tPA and PAI-1 did not change. There was also no effect, on platelet count, APTT, TT and fibrinogen concentration.

Original languageEnglish
Number of pages1
JournalFibrinolysis
Volume10
Issue numberSUPPL. 3
DOIs
Publication statusPublished - 1996 Jan 1

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'The effect of a novel 5HT<sub>2</sub> receptor antagonist sarpogrelate treatment on platelet function and fibrinolysis in Buerger's disease'. Together they form a unique fingerprint.

  • Cite this